Scarica l'app Stockscreener
8.4415
0.98%
-0.1085
Precedente Chiudi:
$8.55
Aprire:
$7.931
Volume 24 ore:
2.00M
Relative Volume:
1.35
Capitalizzazione di mercato:
$734.43M
Reddito:
-
Utile/perdita netta:
$-168.09M
Rapporto P/E:
-3.8901
EPS:
-2.17
Flusso di cassa netto:
$-138.01M
1 W Prestazione:
-2.13%
1M Prestazione:
+14.41%
6M Prestazione:
+2.99%
1 anno Prestazione:
+14.87%
Intervallo 1D:
$7.80
$8.526
Intervallo di 1 settimana:
$7.80
$8.76
Portata 52W:
$5.41
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Nome
Kura Oncology Inc
Settore
Industria
Telefono
(858) 500-8800
Indirizzo
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
8.44 | 744.00M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.69 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.88 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
726.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.44 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
290.22 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-04 | Iniziato | Guggenheim | Neutral |
| 2025-02-06 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-14 | Downgrade | Stifel | Buy → Hold |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-08-11 | Iniziato | BofA Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-05-17 | Iniziato | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2022-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Iniziato | Jefferies | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-11-05 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-11-09 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-13 | Ripresa | Leerink Partners | Outperform |
| 2016-01-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-30 | Iniziato | Oppenheimer | Outperform |
| 2015-12-16 | Iniziato | Citigroup | Buy |
Mostra tutto
Kura Oncology Inc Borsa (KURA) Ultime notizie
Kura Oncology (NASDAQ:KURA) Shares Gap Down After Earnings Miss - MarketBeat
Kura Oncology (NASDAQ:KURA) Releases Earnings Results, Misses Estimates By $0.50 EPS - MarketBeat
Kura Oncology Inc earnings missed by $0.66, revenue fell short of estimates - Investing.com
Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Kura Oncology 10-K: $67.5M revenue; R&D $251.1M, SG&A $120.0M - TradingView
Kura Oncology: Q4 Earnings Snapshot - KVUE
Kura Oncology: Fourth Quarter Financial Results Overview - Bitget
Kura Oncology (KURA) Faces Mixed Financial Results Amid Promisin - GuruFocus
Earnings Flash (KURA) Kura Oncology Posts Q4 Loss $0.92 a Share, vs. FactSet Est of $0.64 Loss - marketscreener.com
KURA ONCOLOGY ($KURA) Releases Q4 2025 Earnings - Quiver Quantitative
Kura Oncology Inc. Q4 Loss Increases - Nasdaq
Kura Oncology Q4 Earnings Summary & Key Takeaways - Benzinga
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results - Yahoo Finance
Kura Oncology at TD Cowen Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
Kura Oncology (KURA) Set to Release Q4 Earnings - GuruFocus
A Glimpse of Kura Oncology's Earnings Potential - Benzinga
Kura Oncology Inc expected to post a loss of 61 cents a shareEarnings Preview - TradingView
Kura Oncology (KURA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Wall Street Zen Downgrades Kura Oncology (NASDAQ:KURA) to Sell - MarketBeat
(KURA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Kura Oncology (NASDAQ:KURA) Upgraded at Zacks Research - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
KURA Should I Buy - Intellectia AI
Kura Oncology, Inc. (KURA): Investor Outlook Reveals 275% Upside Potential - DirectorsTalk Interviews
KURA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Cancer-focused biopharma Kura Oncology sets March 5 call on 2025 results - Stock Titan
Kura Oncology to Participate in Three Upcoming Investor Conferences - marketscreener.com
Biotech firm Kura Oncology maps three March investor talks - Stock Titan
Kura Oncology (NASDAQ:KURA) Rating Increased to Hold at Wall Street Zen - MarketBeat
Will Kura Oncology Inc. stock benefit from upcoming earnings reportsPrice Action & Consistent Profit Focused Trading Strategies - mfd.ru
Kura Oncology, Inc. (KURA): Investor Outlook With A Promising 278% Potential Upside - DirectorsTalk Interviews
Earnings Preview: Kura Oncology (KURA) Q4 Earnings Expected to Decline - Finviz
Kura Oncology (KURA) to Release Quarterly Earnings on Wednesday - MarketBeat
Liquidity Mapping Around (KURA) Price Events - Stock Traders Daily
Kura Oncology (NASDAQ:KURA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
What is Kura Oncology Inc. s P E ratio telling us2025 Price Targets & Accurate Entry and Exit Point Alerts - mfd.ru
Kura Oncology (NASDAQ:KURA) Share Price Crosses Below 50-Day Moving AverageHere's Why - MarketBeat
IPO Launch: Is Kura Oncology Inc a strong candidate for buy and holdJuly 2025 Retail & Free Verified High Yield Trade Plans - baoquankhu1.vn
Is Kura Oncology Inc. vulnerable to short sellersPortfolio Return Report & Daily Price Action Insights - mfd.ru
The Truth About Kura Oncology Inc: Is This Sleeper Cancer Stock About To Explode? - AD HOC NEWS
Kura Oncology (KURA) Issues Stock Options to New Employees - GuruFocus
Kura Oncology Grants Inducement Stock Options to New Employees as Part of 2023 Inducement Option Plan - Quiver Quantitative
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Need To Know: The Consensus Just Cut Its Kura Oncology, Inc. (NASDAQ:KURA) Estimates For 2026 - simplywall.st
Why (KURA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Barclays Remains a Buy on Kura Oncology (KURA) - The Globe and Mail
Analyst flags Kura Oncology, Inc. (KURA) for 2026 milestones and pipeline expansion - MSN
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Analyst Flags Kura Oncology, Inc. (KURA) for 2026 Milestones and Pipeline Expansion - Finviz
Citizens reiterates Market Outperform rating on Kura Oncology stock By Investing.com - Investing.com Canada
Kura Oncology Inc Azioni (KURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.97%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):